Karo Bio is a joint venture between Scios Nova and Swedish Genetic Investment. Karo Bio is a drug discovery company specializing in the field of nuclear receptors and the development of receptor-selective and tissue-selective pharmaceuticals to treat major disorders. The company’s proprietary technology BioKey® is used to validate and screen targets. Karo Bio had net sales of €9.17 M in 2003.